BLACK WEEKSViale −15 % · kompleti −10 % · ostalo −5 %s kodoBrezplačna dostava v Nemčiji od 200 €

Ta stran je bila prevedena samodejno in lahko vsebuje napake. Ste materni govorec? Veseli bomo vaših povratnih informacij in popravkov.Pošljite povratne informacije

The Peptide Desk The Peptide Desk

Te informacije so namenjene izključno raziskovalnim in izobraževalnim namenom. Brez zdravniških priporočil. Izdelki niso odobreni za uporabo pri ljudeh. Za zdravstvena vprašanja se posvetujte z zdravnikom.

Leksikon

Tirzepatide Oral

The dual GIP/GLP-1 agonist as a tablet: the same molecule as the injection, with an absorption nobody has measured in humans.

6 min read 8 sources

White tablet bottle with a black TPD label for Tirzepatide Oral on a white podium, next to it a large, branched molecule model of blue and white glass spheres in a bright lab
Compound approved · injection only, since 2022 according to ChEMBLLaboratorijsko testirano v trgovini

Summary

At a glance

Sources checked on 26 Oct 2026

Tablet in humans
0 trials

registry search for oral tirzepatide without results, as of 26 Oct 20266

Oral bioavailability (semaglutide)
0.8 %

the only approved GLP-1 peptide to swallow, as a reference model3

Day-to-day variability
137 %

oral semaglutide, 33% at steady state with daily intake3

Weight with the injection
-20.9 %

SURMOUNT-1, highest level, 72 weeks, placebo -3.1%1

Targets
2 receptors

GIP and GLP-1, each as an agonist according to ChEMBL8

  • Tirzepatide is a dual agonist at the receptors for GIP and GLP-1. The peptide was developed for a weekly injection under the skin.82
  • With the injection, weight fell by up to 20.9 percent after 72 weeks in SURMOUNT-1, by 3.1 percent on placebo.1
  • There is no human trial for a tablet. A 2026 study showed measurable levels in rats and dogs with the absorption enhancer sodium caprate.65
  • Oral semaglutide serves as a reference: bioavailability 0.8 percent, depending on fasting time and water volume, with strong day-to-day variability.3
  • Only the injectable compound is approved. Everything here is the state of research, not a recommendation.8
Profil

Updated October 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~5 days

Half-life ~5 days
After 10 days: 25 %
Day 1, next dose · 87 %Day 5 · 50 %Day 10 · 25 %Day 15 · 12.5 %Day 25 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
Dual GIP / GLP-1 agonist

oral

Form
Tablet

500mcg, 25 per pack

Use
Once daily in the morning

fasted, with a little water

Half-life
~5 days

molecule, still taken daily

Bioavailability
Not measured in humans

typically below 1 percent for oral peptides

Status
Experimental

no approved tablet form

Sizes
500mcg/25tabs

1 size in the shop

Vsebina 13 sections
  1. Na prvi pogled
  2. What is Tirzepatide Oral?
  3. How it works
  4. Use and dosing
  5. Use when switching from the injection
  6. What the research shows
  7. Stanje raziskav
  8. Side effects
  9. Storage
  10. Sorodne spojine
  11. Pogosta vprašanja
  12. Slovar pojmov
  13. Viri

What is Tirzepatide Oral?

Tirzepatide Oral is the same active compound as injectable tirzepatide, just pressed into a tablet: a dual agonist at the GIP and GLP-1 receptors, here at 500mcg per tablet with 25 tablets per pack. The idea is simple, the same incretin effect without a needle.

The catch is absorption. Tirzepatide is a 39-amino-acid peptide with an attached fatty acid. Peptides are largely digested in the stomach and gut before they reach the blood. The molecule was designed for once-weekly subcutaneous dosing (Coskun, 2018). There is no approved tablet form. No clinical study of oral intake in humans has been published so far. That makes the tablet an experimental product for people who do not want to inject, not the better option.

This information is for research and educational purposes only. No medical advice.

Comparison

Tablet or injection

Same receptors, a different route into the blood. Tap a card to open its entry.

According to ChEMBL: tirzepatide activates the GIP and GLP-1 receptors (approved 2022), semaglutide the GLP-1 receptor (approved 2017). Oral semaglutide is absorbed in the stomach with the enhancer SNAC. 84

How it works

Once in the bloodstream, tirzepatide does what it does from a syringe: it activates the GIP and GLP-1 receptors at the same time. The result is a glucose-dependent boost in insulin release, slower gastric emptying and stronger satiety signalling in the brain. Many describe food noise quieting down and portions shrinking.

The difference from the injection is the route in. After swallowing, the peptide meets stomach acid and digestive enzymes. Only a tiny fraction crosses the mucosa. Oral peptide tablets therefore rely on absorption enhancers that buffer local pH, slow enzymes and briefly loosen the mucosal barrier. For the only approved oral GLP-1 peptide, oral semaglutide with the enhancer SNAC, uptake happens directly in the stomach (Buckley, 2018). Measured bioavailability is around 0.8 percent (Overgaard, 2021).

For the tirzepatide tablet, nothing is published about whether and which enhancer it contains or how much actually reaches the blood in humans. Studies suggest that tirzepatide can in principle be absorbed orally with sodium caprate as the enhancer, but so far only in a cell model and in rats and dogs (Im, 2026). The half-life of the molecule is about five days. Daily intake is there to even out the low and variable absorption, not to compensate for fast breakdown.

Where it acts

Where tirzepatide and oral peptides acted in studies

Tap a point or a card. Colour = receptor, grey = observed in studies (also injection or semaglutide).

  1. Stomach

    Oral semaglutide is absorbed directly in the stomach and needs the enhancer SNAC4

    Observed in trials
  2. Pancreas

    Glucose-dependent insulin release via both receptors (mice)2

    GIPGLP-1
  3. Fat tissue

    Weight down by up to 20.9 percent after 72 weeks with the injection1

    Observed in trials
  4. Blood

    Measurable levels after a tablet with sodium caprate in dogs5

    Observed in trials

Targets in the ChEMBL database8

Compound CHEMBL4297839: two recorded mechanisms, all Agonist.

GIP receptor
Gene
GIPR
UniProt
P48546
ChEMBL
CHEMBL4383
Action
Agonist
GLP-1 receptor
Gene
GLP1R
UniProt
P43220
ChEMBL
CHEMBL1784
Action
Agonist
Glass stomach lining, blue molecules pass through to yellow fat cells with blue docking sites
Only a small part of a swallowed peptide crosses the mucosa. Symbolic image.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
Closed white tablet bottle with a black TPD label for Tirzepatide Oral, a glass of water and a few white tablets beside it
In the morning on an empty stomach with little water, then wait. Symbolic image.

Use when switching from the injection

Dosing. Loading the dosing information …

What the research shows

The evidence splits in two. For the compound itself it is overwhelming: in SURMOUNT-1, participants on once-weekly subcutaneous tirzepatide lost a dose-dependent average of 15 to 20.9 percent of body weight over 72 weeks, versus 3.1 percent on placebo (Jastreboff, 2022). The path from molecule to first human study is described by Coskun (2018): a fatty-acid-modified peptide built for once-weekly subcutaneous dosing.

For the tablet there is none of that in humans. What exists is formulation research: a 2026 paper developed a tirzepatide tablet with sodium caprate as absorption enhancer and showed better permeability in a cell model and measurable blood levels in rats and beagle dogs (Im, 2026). That proves the route works in principle. It does not prove how well it works in humans, let alone how much of a given tablet gets in.

The best reference point is therefore oral semaglutide, the only approved GLP-1 peptide you can swallow: bioavailability around 0.8 percent under the recommended intake conditions, day-to-day variability of 137 percent, which smooths out to about 33 percent at steady state with daily dosing (Overgaard, 2021). Translated: with oral peptides, daily disciplined intake is not a detail, it is the precondition for a stable level to build up at all.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Body weight after 72 weeks1

SURMOUNT-1, 2,539 adults with obesity, weekly injection, not the tablet

Weight change1
Placebo -3.1%
Lowest level (injection) -15.0%
Middle level (injection) -19.5%
Highest level (injection) -20.9%

Values from the abstract (treatment-regimen estimand). How much of a tablet reaches the blood has not been measured in humans, the figures cannot be transferred.

Lost at least 5 percent of weight1

Share of participants after 72 weeks, SURMOUNT-1

At least 5 percent1
Placebo 35%
Lowest level (injection) 85%
Middle level (injection) 89%
Highest level (injection) 91%
At least 20 percent1 no value in the abstract for the lowest level
Placebo 3%
Middle level (injection) 50%
Highest level (injection) 57%

Values from the abstract. Applies to the weekly injection.

How a GLP-1 peptide from a tablet arrives3

Oral semaglutide with the enhancer SNAC, data from clinical pharmacology trials

Bioavailability3 as specified: 30 minutes fasting, at most 120 ml of water
Oral semaglutide (reference model) 0.8%
Day-to-day variability3
Oral semaglutide (reference model) 137.0%
Variability at steady state3 with daily intake
Oral semaglutide (reference model) 33.0%

Values from the abstract, measured with semaglutide, not tirzepatide. Waiting longer after the tablet raised absorption, more water lowered it.

Glass display case with a glass stomach and a frosted glass pancreas on a white plinth
Trials of the compound as an injection and formulation research on the tablet. Symbolic image.

Research status

Where the research stands

ClinicalTrials.gov lists no trial of tirzepatide as a tablet. Shown are trials of the same compound as an injection, including the first human study, two studies on gastric emptying and the contraceptive pill and SURMOUNT-1. As of 26 Oct 2026. 7

  1. Preclinical Tablet with sodium caprate: cell model, rats and dogs
  2. Phase 1 3 trials, 3 completed
  3. Phase 2 no registered trial
  4. Phase 3 1 trial, 1 completed
  5. Approval injection only, since 2022 according to ChEMBL
2,539 participants in phase 3 Only the injection is approved: ChEMBL lists tirzepatide with phase 4 as the highest phase and first approval in 2022. No tablet form is approved.8
Show all 1 phase 3 trial on a timelineHide timeline 1 completed 0 running 1 with results
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 3 trials on safety and pharmacokinetics, not shown as bars.

Side effects

The side-effect profile belongs to the compound, not the tablet: nausea, fullness, belching, diarrhea or constipation, mostly at the start and after each increase. Whether the tablet is harder on the stomach than the injection has not been studied, but here compound and tablet excipients land directly on the gastric lining. The slow entry is exactly what guards against this.

  • Appetite and fluids: with little hunger you often drink less too. Keep fluids and protein up, otherwise more muscle is lost along with fat.
  • Variable absorption: unlike the injection, the effect can differ from day to day. A strong day is no reason to take less the next. A weak day is no reason to go up either.
  • Rare class signals: gallbladder trouble with rapid weight loss, rarely pancreatitis, thyroid C-cell tumors in rats. With persistent severe abdominal pain, stop and get it checked.
  • Other tablets: delayed gastric emptying can shift the absorption of other oral compounds, according to the injection label including oral contraceptives (it advises adding a barrier method for four weeks after starting and after each increase). Combined with insulin or sulfonylureas the risk of hypoglycemia rises.

Solid human data on the tolerability of the tablet itself, for example on whether and which absorption enhancer it contains, do not exist. That is the price of an experimental product.

Tolerability

Stopped due to side effects (injection)

Out of 100 participants per group, how many had the event over 72 weeks with the injection.

3 of 100 Placebo
4 of 100 Lowest level (injection)
7 of 100 Middle level (injection)
6 of 100 Highest level (injection)
Event PlaceboLowest level (injection)Middle level (injection)Highest level (injection)
Stopped due to adverse events1 3%4%7%6%

Values from the abstract. Gastrointestinal effects were most common, mostly mild to moderate and mainly during dose escalation. There are no human data for the tablet.16

Storage

Tablets are low-maintenance: store dry, cool (not above 25 degrees) and protected from light in the tightly closed original container, not in the bathroom or kitchen where humidity and heat swing. A fridge is not needed, what matters is that no moisture gets to the tablets.

Swallow the tablets whole, do not split, crush or chew them: oral peptide tablets are designed to reach the stomach intact. For oral semaglutide this is an explicit part of the intake instructions. Keep out of reach of children and mind the expiry date.

Three white capsule bottles on a bright shelf next to a folded light blue towel
Store dry, cool and protected from light in the closed container. Symbolic image.
Level · Tirzepatide Oral

Kako se raven gradi

One dose per day: vsak odmerek se doda k ostanku prejšnjega.

Leksikon: Once daily in the morning, fasted, with a little water
Peak 7.73×Trough 6.73×
Day 21 · 22. dose
7.36× of the first dose
Plateau
from Day 21

95 % of the plateau after dose 22

Peak
7.73×

of the first dose

Trough
6.73×

before the next dose

Poenostavljen model, vrednosti relativne glede na prvi odmerek, brez podatkov o odmerjanju. Črtkano: samo prvi odmerek, zeleno: plato.

Related

Related compounds

Same receptors or a different path: all in the TPD lexicon.

FAQ

Common questions about Tirzepatide Oral

Short answers, each backed by the sources below.

Is tirzepatide approved as a tablet?

No. The compound is approved only as an injection, since 2022 according to ChEMBL. ClinicalTrials.gov lists no trial of oral tirzepatide, as of 26 October 2026.86

How much of a tablet reaches the blood?

For tirzepatide this has not been measured in humans. For oral semaglutide, the only approved GLP-1 peptide to swallow, it is about 0.8 percent. Absorption varies by 137 percent from day to day and evens out to about 33 percent with daily intake.3

Is there research on a tirzepatide tablet?

Yes, but only preclinical. A 2026 study developed a tablet with sodium caprate as an absorption enhancer. In a cell model permeability improved, in rats and beagle dogs blood levels were measurable.5

Why does fasting matter so much?

With oral semaglutide absorption depended mainly on the fasting time after the tablet and on the water volume. Waiting longer raised it, more water lowered it. Absorption takes place directly in the stomach close to the tablet.34

What do the trials on the compound itself show?

With the weekly injection weight fell by 15.0 to 20.9 percent after 72 weeks in SURMOUNT-1, by 3.1 percent on placebo. These figures apply to the injection and cannot be transferred to the tablet.1

Which side effects are described?

For the compound mainly gastrointestinal effects such as nausea, vomiting, diarrhoea and reduced appetite, depending on the dose. In SURMOUNT-1 4.3 to 7.1 percent stopped because of side effects, 2.6 percent on placebo. There are no human data for the tablet itself.21

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Absorption enhancer
Excipient in the tablet that locally buffers stomach acid and briefly makes the mucosa more permeable.
Agonist
Compound that activates a receptor like the body's own messenger.
Bioavailability
Share of a swallowed dose that reaches the blood unchanged.
GIP
Gut hormone that boosts insulin release after a meal.
GLP-1
Gut hormone that stimulates insulin, slows gastric emptying and creates satiety.
Half-life
Time until half of a compound in the blood has been cleared.
Incretin
Umbrella term for gut hormones such as GIP and GLP-1 that stimulate insulin after a meal.
Peptide
Short chain of amino acids. In the stomach it is easily digested.
SNAC
Absorption enhancer in oral semaglutide. It protects the peptide in the stomach and helps absorption.
Sodium caprate
Salt of a fatty acid studied as an absorption enhancer for peptide tablets.
Subcutaneous
Injected under the skin, into the fat tissue.

Dokazi

Viri

Show all 8 sourcesHide sources 5 Studies2 Trial registry1 Database checked 26 Oct 2026

Studies

  1. SURMOUNT-1: tirzepatide as a weekly injection in obesity

    Jastreboff et al., New England Journal of Medicine, 2022

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Development of the dual agonist up to the first human study

    Coskun et al., Molecular Metabolism, 2018

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Pharmacokinetics of oral semaglutide (reference model)

    Overgaard et al., Clinical Pharmacokinetics, 2021

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Stomach absorption of an oral GLP-1 peptide with SNAC

    Buckley et al., Science Translational Medicine, 2018

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Tirzepatide tablet with sodium caprate, preclinical

    Im et al., Pharmaceutics, 2026

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Registry search for oral tirzepatide (0 results)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. All trials with tirzepatide on ClinicalTrials.gov (injection)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Tirzepatide, semaglutide and orforglipron in ChEMBL (targets and approval)

    ChEMBL, EMBL-EBI (CHEMBL4297839, CHEMBL2108724, CHEMBL4446782)

    Checked 26 Oct 2026 via ChEMBL

V trgovini

Tirzepatide Oral in the catalog

Velikosti, cene in časi odpreme so na strani izdelka.

Na izdelek